Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Mary Choi
Weill Medical Coll of Cornell Univ, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Proterris
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Augustine Choi, immediate family member of Dr. Mary Choi, is the cofounder of Proterris, a private company that aims to develop carbon monoxide (CO) therapeutically. Under the regulation, investigators must disclose significant financial interests not only for themselves, but of his/her spouse and dependent children.
The aims of the NHLBI funded research are to
1. To characterize the function of RIPK3 and MLKL in the pathogenesis of organ fibrosis;
2. To determine the pathogenic contribution of RIPK3-regulated fatty acid (FA) synthesis in fibrotic organs; and
3. To determine the role of the RIPK3 and the FA synthesis pathways in the therapeutic effects of CO in experimental lung and kidney fibrosis, and in human fibrosis.
The institution has determined that the third aim creates a financial conflict of interest because it overlaps with the business interests of Proterris.
Novel role of RIPK3-dependent necroptosis pathway in lung and kidney fibrosis
Project Narrative Fibrosis, which leads to progressive loss of tissue function and eventual organ failure, contributes significantly to the global burden of disease. These studies will uncover new candidate markers for disease severity, and also potentially identify new molecular targets for diagnostic and therapeutic approaches to managing patients with organ fibrosis, which are urgently needed.
Filed on September 14, 2017.
Tell us what you know about Mary Choi's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Mary Choi filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Mary Choi | Weill Medical Coll of Cornell Univ | Conflict of Interest | Proterris | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.